Focus: Sagent Pharmaceuticals is a specialty pharmaceutical company focused on injectable small molecules, headquartered in Schaumburg, Illinois. The company operates primarily in a mature, post-LOE portfolio with significant revenue concentration in established products.
Profile data last refreshed 8h ago · AI intelligence enriched 2w ago
Sagent offers stability in a niche injectable space but poses career risk due to razor-thin pipeline, heavy single-product revenue reliance, and virtually frozen hiring.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship revenue driver representing 56% of company revenue; cyclic lipopeptide antibiotic for Gram-positive infections.
Help build intelligence for Sagent Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Sagent Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Topical local anesthetic for urologic and procedural applications; second-largest revenue contributor post-LOE.
Generic daptomycin formulation contributing incremental revenue; indicates commoditization pressure on flagship asset.
Essential electrolyte replacement therapy; mature, low-margin utility injectable.
Neonatal respiratory support agent; niche pediatric indication with stable chronic utilization.
NSAID injectable for perioperative pain; generic competition limits differentiation.
Anticholinergic for pediatric neurologic symptom management; highly specialized, low-volume indication.
Bone metabolism agent facing biologic and oral therapy competition; waning market relevance.
5-HT3 receptor antagonist for emetogenic chemotherapy and surgery; commodity generic market.
Potent vasodilator for acute hemodynamic management; limited to hospital formularies with cyanide toxicity risk requiring monitoring.
23 discontinued, 61 duplicate formulations not shown
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
+64 more products
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo